Study of Neumora’s early-stage schizophrenia drug on hold, reports ET HealthWorld

Neumora Therapeutics, a pharmaceutical company, faced a setback as the U.S. Food and Drug Administration (FDA) imposed a clinical hold on the early-stage study of its experimental schizophrenia drug. The decision came after pre-clinical data revealed uncontrollable muscle contractions or convulsions in rabbits. As a result, Neumora’s shares plummeted more than 23% in premarket trading.

The company had dosed about 30 participants in the early-stage study, with no instances of convulsions reported among the participants. Despite this, the FDA determined it necessary to pause the study to address the safety concerns raised by the pre-clinical data.

Neumora Therapeutics, which is supported by Amgen and Japan’s SoftBank, is currently collaborating with the FDA to resolve the clinical hold and ensure the safety of its experimental schizophrenia drug. The company made its debut on the Nasdaq in September, showcasing the potential of its innovative drug development efforts.

The FDA’s decision has raised questions about the future trajectory of Neumora Therapeutics and its experimental drug in the treatment of schizophrenia. Investors and stakeholders await further updates on the resolution of the clinical hold and the company’s path forward in advancing its drug development pipeline.